X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Fact Sheet, VENUS REMEDIES Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Fact Sheet   (VSRM)

Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

VENUS REMEDIES Price History

Price Rs 104.1
Mkt Cap Rs m 1,191
Vol '000 62.5
P/E X -930.4
P/CF X 2.7
EPS (TTM) Rs -0.1
% ch % -2.0
No. of shares m 11.44
% ch week % 8.7
% ch 1-mth % 13.2
% ch 12-mth % -1.0
52 week H/L Rs 142.8/80.0
(As on Sep 22, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

VENUS REMEDIES Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
VENUS REMEDIES EQUITY SHARE DATA
High Rs276328358330218 
Low Rs14115814010382 
Sales per share (Unadj.) Rs420.8444.6473.4405.6365.6 
Earnings per share (Unadj.) Rs48.354.456.24.51.5 
Diluted earnings per shareRs41.150.156.24.51.5 
Cash flow per share (Unadj.) Rs74.285.891.444.737.9 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs2.552.760.000.000.00 
Dividend yield (eoy) %1.41.2000 
Book value per share (Unadj.) Rs315.5359.7403.5399.2382.5 
Adj. book value per shareRs268.6331.4403.5399.2382.5 
Shares outstanding (eoy) m9.7410.5411.4411.4411.44 
Bonus/Rights/Conversions  WCWCWC-- 
Price / Sales ratio x0.50.50.50.50.4 
Avg P/E ratio x4.34.54.447.9101.0 
P/CF ratio (eoy) x2.82.82.74.84.0 
Price / Book Value ratio x0.70.70.60.50.4 
Dividend payout %6.25.5000 
Avg Mkt Cap Rs m2,0312,5602,8492,4711,717 
No. of employees `000NANANANA1.0 
Total wages/salary Rs m248273305324324 
Avg. sales/employee Rs ThNMNMNMNM4,100.7 
Avg. wages/employee Rs ThNMNMNMNM318.0 
Avg. net profit/employee Rs ThNMNMNMNM16.7 
VENUS REMEDIES INCOME DATA
Net Sales Rs m4,0984,6865,4164,6404,183 
Other income Rs m545720 
Total revenues Rs m4,1034,6915,4204,6474,203 
Gross profit Rs m1,0311,2011,382892812 
Depreciation Rs m252331402460417 
Interest Rs m275246294412380 
Profit before tax Rs m5096286912735 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m385548-2518 
Profit after tax Rs m4715736435217 
Gross profit margin %25.225.625.519.219.4 
Effective tax rate %7.48.86.9-94.851.6 
Net profit margin %11.512.211.91.10.4 
VENUS REMEDIES BALANCE SHEET DATA
Current assets Rs m1,6962,2562,7212,6752,771 
Current liabilities Rs m1,5321,9132,1101,9651,931 
Net working cap to sales %4.07.311.315.320.1 
Current ratio x1.11.21.31.41.4 
Inventory Days Days8610096112125 
Debtors Days Days3637445054 
Net fixed assets Rs m2,0544,0565,0735,2195,328 
Share capital Rs m97105114114114 
"Free" reserves Rs m2,0782,6064,4504,4454,177 
Net worth Rs m3,0733,7914,6164,5674,376 
Long term debt Rs m9911,2911,4001,6861,911 
Total assets Rs m5,7407,1768,3448,4118,428 
Interest coverage x2.83.63.31.11.1 
Debt to equity ratio x0.30.30.30.40.4 
Sales to assets ratio x0.70.70.60.60.5 
Return on assets %13.011.411.25.54.7 
Return on equity %15.315.113.91.10.4 
Return on capital %19.317.216.47.06.6 
Exports to sales %00000 
Imports to sales %13.214.817.017.720.5 
Exports (fob) Rs m00000 
Imports (cif) Rs m542695921821858 
Fx inflow Rs m00000 
Fx outflow Rs m00921822858 
Net fx Rs m00-921-822-858 
VENUS REMEDIES CASH FLOW
From Operations Rs m 417 522 527 678 469 
From Investments Rs m -952 -1,039 -947 -672 29 
From Financial Activity Rs m 533 552 401 -14 -464 
Net Cashflow Rs m -2 34 -20 -8 35 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 32.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 0.6%
ADR/GDR 0.0%
Free float 66.4%
Shareholders 20,121
Pledged promoter(s) holding 36.4%
 

Company Information

REGD OFF SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
E-MAIL investorgrievance@venusremedies.com WEB www.venusremedies.com
TELEPHONE (0172) 393 3094 FAX (0172) 256 5566
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
AUDITOR J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   SANOFI INDIA  PANACEA BIOTECH  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare VENUS REMEDIES With:   SANOFI INDIA  PANACEA BIOTECH  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week; Realty & Metal Stocks Plunge(Closing)

Indian share markets continued to languish in red in the afternoon session as rupee hit its weakest point since early April amid concerns.

Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - DR. REDDYS LAB COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS